In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled with the discovered monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section C, https://abbv-744-preclinical-stud46891.bloggosite.com/38775926/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers